Epstein-Barr virus (EBV)-carrying Burkitt lymphoma (BL) cells are relatively or completely resistant to the lytic effect of major histocompatibility complex class I HLA antigen-restricted cytotoxic T lymphocytes (CTLs) generated by stimulating lymphocytes of EBV-seropositive donors with the autologous EBV-transformed lymphoblastoid cell line (LCL). We previously found that EBV-negative and EBVcarrying BL lines derived from HLA-All-positive donors were not only resistant to lysis by the HLA-All-restricted CTL generated by stimulation with the autologous LCL, but also to HLA-All-specific CTL derived from lymphocytes of an EBVseronegative donor stimulated with an allogeneic LCL. Using the same and additional cell lines, we now show that the CTL resistance of the BL lines is probably due to a selective down-regulation of HLA-All. We also show that the EBVencoded latent membrane protein is expressed at a lower level in the EBV-carrying BL lines than in EBV-transformed LCLs. Only one of eight in vitro EBV-converted BL lines that shifted to a more LCL-like growth pattern expressed LMP at a high level. This line also reexpressed the HLA-All antigen that was undetectable in its EBV-negative progenitor. Our rmdings suggest that the typical BL cell phenotype is associated with low expression of both proteins.
Reciprocal translocations juxtapose the cellular c-myc gene (MYC gene in humans) to an immunoglobulin locus in Epstein-Barr virus (EBV)-carrying and EBV-negative Burkitt lymphoma (BL) lines and in mouse and rat plasmacytomas (1, 2) . It has been suggested that the translocations contribute to the tumorigenic process by bringing the c-myc gene under the regulatory influence of the adjacent, highly active immunoglobulin locus. This concept is supported by the high incidence of pre-B-cell and B-cell lymphomas in transgenic mice that carried immunoglobulin heavy chain Igh enhancer-myc constructs (3) and the appearance of translocation-free plasmacytomas in pristane oil-treated BALB/c mice infected with myc-expressing retroviral constructs (4) . However, the monoclonality of the B-cell tumors that arose in the transgenic mice carrying the Igh enhancer-myc construct indicates that at least one additional step is needed for full tumorigenicity.
EBV-carrying BL cells are relatively or completely resistant to the lytic effect of major histocompatibility complex (MHC) class I HLA antigen-restricted cytotoxic T lymphomas (CTLs) generated by stimulating lymphocytes of EBVseropositive donors with the autologous EBV-transformed lymphoblastoid cell line (LCL) (5, 6) . This was taken to suggest that escape from immune surveillance may play a role in the pathogenesis of the EBV-positive BL lines.
We have found that EBV-negative and EBV-carrying BL lines derived from HLA-A1l-positive donors were not only resistant to lysis by the HLA-All-restricted CTLs generated by stimulation with the autologous LCL but also the HLAAll-specific CTLs generated by stimulating the lymphocytes of an EBV-seronegative donor with an allogeneic LCL (6 (12) that react with activation antigens expressed on all LCLs, J5 (13) directed to the common acute lymphoblastic leukemia antigen (CALLA), and 38. 13 (14) that binds to a BL-associated antigen (BLA). The phenotype was classified as described by Rowe et al. (15) ratio of cells exposed to the fluorescein isothiocyanateconjugated rabbit anti-mouse antibodies alone.
Establishment and Characterization of CTL Clones. Activation of CTL and cloning were performed as described (6) . Clones WP-21, -38, and -5 were obtained by stimulating the lymphocytes of an EBV seronegative donor (WP) with the allogeneic LCL SJ-B-1 (HLA-A1l/A24, -B7/B27). Clones 171-1 and 139-cult were obtained by stimulating the lymphocytes of healthy donors with the IARC-171 and IARC-139 LCLs. All clones expressed the T-cell differentiation markers CD3 and CD8. HLA specificity was demonstrated by the selective killing of allogeneic targets matched to a single HLA-A or -B antigen. The IE-B-1 LCL and IE-T-blasts were derived from a healthy donor (HLA-A3/A11, -B7/B35). T blasts were gene-rated by stimulating peripheral blood lymphocytes with 5 ,ug of concanavalin A per ml for 3 days. The specificity of the 139-cult could not be determined because of a lack of appropriate HLA matching targets. Saturating concentrations of the W6/32 mAb blocked cytotoxicity. K562, Daudi, and other natural killer cell-sensitive targets were not killed.
lInmunoblotting and Immunodotting. Total cell extracts were prepared by resuspending 5 x i07 cells in 1 ml of 20 mM Tris buffer (pH 7.5) containing 1% Nonidet P-40, 1% Na deoxycholate, 0.1% NaDodSO4, 2 mM phenylmethylsulfonyl fluoride, 4 mM EDTA, and 400 mM NaCl. The cell suspensions were sonicated and centrifuged for 20 min at 10,000 x g. Supernatants (20 ,ul) were resuspended in 80 ,u1 of sample buffer and electrophoresed in NaDodSO4/7.5% polyacrylamide gels by the method of Laemmli (18) . Molecular weight determinations were made by running high and low molecular weight standards (Bio-Rad) in the same gels. Immunoblotting was performed as described (19) . The blots were probed with the mAb S-12 directed to an antigenic determinant on the carboxyl-terminal part of the LMP molecule (20) or with previously characterized human sera containing antibodies to EBV-determined nuclear antigens (EBNAs) 1, 2, 3, and 4 (21) .
Serial dilutions of total cell extracts were made from a starting concentration equivalent to 106 cells by double dilution in phosphate-buffered saline. The extracts were blotted on nitrocellulose filters prewetted in phosphatebuffered saline by using a dot-blot apparatus (Bio-Rad) under mild suction. After drying in air, the nitrocellulose sheets were stained with Ponceau-S to ascertain that equal amounts of proteins had been loaded for each cell line and were probed with the S-12 mAb.
RESULTS
Phenotypic Characteristics of the Cell Lines. These are listed in Table 1 . All EBV-negative BL lines expressed a group I phenotype as expected (15) . The two EBV-positive BL lines that originally belonged to group I had drifted to a more LCL-like group II phenotype during in vitro passage. The EBV-converted BL-28 sublines remained phenotypically similar to their progenitor, while the BL-41 convertants progressed to group II. This phenotypic switch was stable in lines converted with the transforming B95-8 substrain of EBV, whereas two lines that converted with the transformation-defective P3HR1 substrain lost part of their activation markers.
Sensitivity of LCL and BL Lines to Allospecific Cytotoxicity. Three EBV-negative (BL-28, BL-41, and DG-75) and the EBV-positive (WW-1-BL and BL-72) BL lines derived from HLA-A1l-positive patients were resistant to HLA-A1l-specific CTLs that lysed the LCLs derived from the same donors and HLA-A11-positive T and B blasts (Fig. 1) . Two of the EBV-negative lines, BL-28 and BL-41, were converted to EBV-positive lines by exposing them to the B95-8 and P3HR1 viral substrains. Both independently converted BL-28 sublines and five of the six converted BL-41 sublines were as resistant to HLA-A11-specific lysis as were their EBV-negative progenitors. The sixth convertant, BL 41/95, became sensitive, but at a lower level than the LCL derived from the same donor (Fig. 2) .
BL lines are not generally resistant to cell-mediated cytotoxicity. They are as sensitive to natural killer cells and to interferon-and mixed lymphocyte culture-activated nonspecific killer cells as were the corresponding LCLs (9, 22) . Moreover, as shown in Fig. 1 , at least three of the anti-HLAAll CTL-resistant BL lines were equally sensitive to CTLs directed against the HLA class I specificities B27, A24, and B35 as were the corresponding LCLs.
Down-Regulation of HLA-All in BL Cells. Previous studies (5, 6) detected no systematic difference in the MHC class I antigen expression of BL and LCL lines, as judged by their reactivity with an anti-MHC class I framework mAb. We now have compared LCL and BL lines derived from HLA-A11-positive donors with regard to their ability to bind the same antibody (W6/32), in comparison with the AUF 5.13 mAb directed against a polymorphic determinant shared by HLA-A3 and -All (17). There was no major difference in the binding of W6/32, while AUF 5.13 binding was strongly reduced in all five BL lines, suggesting that their resistance to anti-HLA-A11 CTLs is due to a selective decrease of HLA-A11 expression (Fig. 3) (Fig. 4) as expected (20, 23) . In the two EBV-positive BL lines WW-1-BL and BL-72, LMP appeared as a weak band of -58 and -62 kDa, respectively. BL 41/95 was unique among the EBV-converted lines in expressing a readily detectable 62-kDa LMP band. A weak band was detected in E95B-BL-28 and E95B-BL-41 in some of the blots. The relatively low expression of LMP in the EBV-carrying BL cells was confirmed by immunodotting analysis of serially diluted whole-cell extracts (Fig. 5) LMP is the major EBV-encoded membrane antigen in growth-transformed cells (20, 26) and, therefore, is regarded as a probable target for EHV-specific CTLs (26, 27 phenotypes after prolonged in vitro culture (11) . Similar changes could be induced in some EBV-negative BL lines by in vitro EBV conversion (15, 28 
